Table 1.
Characteristics of the Included Studies
| Study | Year | Location | No. of Patients | Trial Phase | Capecitabine Based | Capecitabine Free | Capecitabine Schedule (mg/m2, Cycles) | Follow-Up (Median Years) |
|---|---|---|---|---|---|---|---|---|
| CBCSG-1021 | 2016 | China | 561 | III | TX-XEC | T-FEC | 1,000, 6 | 2.5 |
| FinXX20 | 2016 | Finland | 1,495 | III | TX-CEX | T-CEF | 900, 6 | 10.3 |
| GAIN24 | 2014 | Germany | 2,994 | III | EC-TX | ETC/idd-ETC | 1,000–1,250, 4 | 6.2 |
| GEICAM/2003-1019 | 2015 | Spain | 1,384 | III | ET-X | EC-T | 1,250, 4 | 6.6 |
| ICE II-GBC 5223 | 2015 | Germany | 391 | II | nPX/PX | EC/CMF | 1,000, 6 | 2 |
| TACT222 | 2014 | UK | 4,358 | III | E-X | E-CMF | 1,250, 4 | 5 |
| USON 0106218 | 2015 | USA | 2,611 | III | AC→TX | AC→T | 825, 4 | 5 |
| XH Zhang et al.25 | 2015 | China | 278 | II | AX | AC | 1,000, 4 | 4 |
T, docetaxel; X, Xeloda/capecitabine; E, epirubicin; F, fluorouracil; C, cyclophosphamide; ST, standard treatment; M, methotrexate; A, doxorubicin; idd, intense dose-dense; I, ibandronate; P, paclitaxel; nP, nab-paclitaxel.